ALEPH-FARMS
8.12.2021 12:11:09 CET | Business Wire | Press release
Aleph Farms , the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells and WACKER , a supplier of leading protein production technologies, today announced the development of streamlined production processes for essential growth medium proteins to cost-effectively grow cultivated meat. These proteins, central to promoting and supporting cell growth, are not widely available in the market today and represent one of the most prohibitive expenses in scaling up cultivated meat. The agreement between WACKER and Aleph Farms is non-exclusive, meaning any cultivated meat company will be able to obtain these same affordable proteins, without using fetal bovine serum (FBS) or animal-derived ingredients. This open supply chain solution is expected to enable the industry to scale and achieve price-parity faster, eliminating a key hurdle in the commercial viability of cultivated meat.
"Bringing down the cost and making suitable raw materials available at this key moment in the scale-up of production is imperative to taking cultivated meat mainstream and driving impact”, said Didier Toubia, Co-Founder and CEO of Aleph Farms. "Investing in the development of a supply chain solution available to the entire industry is a direct result of our innovative and inclusive business model and the impetus behind our partnership with WACKER.”
WACKER brings over 20 years of experience in protein production to the partnership, as well as a deep understanding of the food industry’s requirements and regulations. At its corporate research labs in Munich, WACKER is working on fermentation techniques for producing cell culture proteins for use in food applications, which will have the same composition of proteins produced inside the animal’s body. Similar production techniques are widely used today to produce enzymes for food processing applications.
“The market for cultivated meat is advancing rapidly and we want to contribute to making it an affordable reality for everyone,” said Susanne Leonhartsberger, president of WACKER BIOSOLUTIONS, WACKER´s life science division. “At WACKER, we have many years of experience in the field of protein production. Our scientists have developed advanced production technologies that we can draw on. With this platform, we are now entering the field of cultivated meat. As the most technologically advanced company in the field, Aleph Farms is an ideal partner for us in this project.”
“Our team’s scientific expertise alongside WACKER’s vast experience makes it possible to produce proteins at the quantity, quality and cost necessary to meet Aleph’s aggressive goal of achieving cost-parity with conventional meat.", said Ayelet Maor Shoshani Ph.D., Director of Cell Line and Media Development at Aleph Farms.
Growth-medium proteins are essential components naturally found in animals and today represent the main cost drivers of cultivated meat production. They act as a nutrient-rich feed to help cells grow and mature into muscle, fat and collagen-producing cells and are imperative for supporting cellular activity. The aim is for this partnership to realize a significant reduction in the cost of these proteins by matching the standard of quality and scale to the food industry. The proteins are to be made available to all cultivated meat companies in the industry.
About WACKER BIOSOLUTIONS
Using advanced biotech processes, WACKER BIOSOLUTIONS provides tailored, innovative solutions and products to the life-sciences sector – including pharmaceutical proteins, cyclodextrins and fermentation-generated cysteine. The portfolio is additionally complemented with catalog chemicals such as acetylacetone. The division focuses on developing customized solutions for growth sectors, such as food ingredients, pharmaceutical activities and agrochemicals. WACKER BIOSOLUTIONS is the life science division of the Munich based WACKER group. For more information visit www.wacker.com
About Aleph Farms
Aleph Farms grows beef steaks, from non-genetically engineered and non-immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company’s vision is to provide unconditional quality nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
